Cerezen™ Receives European Approval for Alzheimer's Treatment While U.S. Approval Remains Pending
核心洞察
Cerezen™ (搜索), a non-invasive medical device targeting vascular health (搜索) in the brain, has received CE certification in Europe for treating mild cognitive impairment (搜索) and mild Alzheimer's disease (搜索).
Clinical studies demonstrate that patients gained an average of five points on cognitive scales within six months, equivalent to regaining a year's worth of lost function.
Despite receiving FDA "Breakthrough Device" designation in 2021, the treatment remains unavailable to American patients while European patients gain access.
Cerezen™ (搜索), a Michigan-based medical device company, has achieved CE certification under the European Union's Medical Device Regulation (MDR 2017/745) for its non-invasive device to treat mild cognitive impairment (搜索) due to Alzheimer's disease (搜索) or mild Alzheimer's disease. The approval makes it the first and only device certified under the new EU framework for the condition, giving European patients access to a therapy that remains unavailable in the United States despite being developed by an American company.
The device represents a significant departure from conventional Alzheimer's treatments. Rather than targeting the amyloid plaques (搜索) that dominate most drug-based approaches, Cerezen™ (搜索) focuses on restoring vascular health (搜索) in the brain, improving blood flow and oxygenation. According to the company, impaired vascular function was identified by Dr. Alzheimer himself as a root cause of the disease.
Clinical Evidence and Patient Outcomes
Clinical studies have demonstrated that patients with mild cognitive impairment (搜索) or early Alzheimer's can see meaningful improvement within six months of treatment. On average, participants gained five points on standard cognitive scales—an improvement roughly equivalent to regaining a year's worth of lost function.
These gains were achieved without major safety risks and without the need for costly PET scans or drug infusions. More than 70% of Alzheimer's patients would qualify for the therapy, representing a stark contrast to the narrow eligibility and high costs associated with many approved drug treatments.
Regulatory Challenges in the United States
In 2021, the U.S. Food and Drug Administration designated Cerezen™ (搜索) a "Breakthrough Device," acknowledging both its safety profile and its potential to meet a significant unmet medical need. However, despite this recognition and clinical data showing measurable improvement in patients' cognition and daily function, the FDA has yet to approve it for use.
"We made every effort to bring this treatment to U.S. patients first," said Cerezen (搜索) Founder and CEO Manoj Bhargava. "However, it seems politics is more important than people's lives. The current pharmaceutical approaches cost a fortune, and the patient still gets worse."
Bhargava expressed frustration with the regulatory disparity: "It's disheartening to know that American families still can't access it. We've proven it's safe, effective and easy to use. The question is no longer whether it works—it's when regulators will allow it here."
Disease Burden and Treatment Landscape
More than 7 million Americans currently live with Alzheimer's disease (搜索), a number projected to surpass 8.5 million by 2030. The economic toll exceeds $400 billion annually, with caregivers—often family members—bearing much of the emotional and financial burden.
Despite decades of research and billions spent, most available treatments merely slow progression. Few offer improvement, and none come close to a cure. For families facing the disease, even small gains in memory, clarity or independence can make a profound difference.
Path Forward
Cerezen (搜索)'s European certification means that patients there could begin receiving treatment in the near future. In the U.S., the timeline remains uncertain. The company is re-engaging with FDA leadership to reopen its prior application.
"This is an American innovation," said Bhargava. "It was developed, tested, and proven here—but the first patients who'll benefit live across the Atlantic. That's a hard reality to accept."